癌の転移を阻害するアプタマー阻害剤による細胞信号の調節
PubMedで要約を見る
まとめ
この要約は機械生成です。細胞結合を阻害し,PI3K/AKT経路を阻害することで,細胞結合を阻害する新しいアプタマーである細胞骨組み関連タンパク質4 (CKAP4) を標的とする. この戦略はがん治療の有望なアプローチです
科学分野
- 腫瘍学
- 分子生物学
- バイオテクノロジー
背景
- 腫瘍の侵入と転移は癌の進行と死亡率の主な要因です.
- 細胞の信号伝達経路をターゲットにすることが 効果的な抗癌療法の開発に不可欠です
研究 の 目的
- 腫瘍転移を抑制するための細胞骨組み関連タンパク質4 (CKAP4) を標的とする特定のアプタマーを設計し評価する.
- アプタマーが癌細胞の転移を抑制する分子機構を調査する.
主な方法
- CKAP4固有のアプタマーの開発
- 癌細胞におけるアプタマー結合の評価
- α5β1インテグリン内化,線維菌素依存性細胞粘着,および細胞牽引力に対するアプタマー効果の分析.
- CKAP4-DKK1相互作用とPI3K/AKTシグナル伝達経路に対するアプタマーの影響の調査
主要な成果
- アプタメルはCKAP4に特異的に結合し,α5β1インテグリンリサイクルを阻害し,細胞粘着を妨害する.
- アプタメルは,CKAP4- DKK1の相互作用を抑制し,PI3K/ AKT経路を抑制し,AKTのリン酸化を減少させます.
- アプタミーはアクチン細胞骨格の再編成を効果的に阻害し,細胞の移動と転移を減少させます.
結論
- CKAP4に特異的なアプタマーは,細胞粘着とPI3K/ AKTシグナル伝達にシネージ効果を通じた強力な腫瘍転移抑制を示しています.
- このアプタマーベースの戦略は癌治療の新たなアプローチであり,転移抑制の新たな方向性を示しています.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

